Clinician Scientist, Principle Investigator
University of Oxford, United Kingdom
Dr Sarah Gooding is a Cancer Research UK-funded Clinician Scientist at the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, in the group of Prof Ross Chapman, and Consultant Haematologist in the Myeloma Service at Oxford Univeristy Hospitals NHS Foundation Trust. Her research interests include genetic mechanisms of resistance to myeloma therapies, the implemetation of NGS and other novel assays into clinical myeloma care for better delivery of precision medicine, and how copy number aberrations and instability in the myeloma genome may be exploited for therapeutic benefit.